Novartis Ag (NVSEF) Receivables (2009 - 2025)

Novartis Ag has disclosed Receivables across 14 years of filings, most recently posting $10.1 billion for Q4 2025.

• Receivables for Q4 2025 came in at $10.1 billion, up 18.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.1 billion (up 18.29% YoY), and the FY2025 annual result was $10.1 billion, up 18.29% from the prior year.
• Receivables came in at $10.1 billion for Q4 2025 at Novartis Ag, up from $9.1 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $10.1 billion in Q4 2025 to a low of $8.2 billion in Q2 2024.
• The 5-year median for Receivables is $8.7 billion (2021), against an average of $8.8 billion.
• Across the five-year window, Receivables fell 10.52% in 2024 and advanced 18.29% in 2025, its largest moves.
• Novartis Ag's Receivables stood at $8.8 billion in 2021, then rose by 2.57% to $9.0 billion in 2022, then slipped by 7.37% to $8.4 billion in 2023, then gained by 1.93% to $8.5 billion in 2024, then grew by 18.29% to $10.1 billion in 2025.
• The last three Receivables figures came in at $10.1 billion (Q4 2025), $9.1 billion (Q2 2025), and $8.5 billion (Q4 2024), per Business Quant data.